CY1121296T1 - Θραυσματα μη ακυλιωμενης γκρελινης για χρηση στη θεραπεια συνδρομου prader-willi - Google Patents

Θραυσματα μη ακυλιωμενης γκρελινης για χρηση στη θεραπεια συνδρομου prader-willi

Info

Publication number
CY1121296T1
CY1121296T1 CY20191100034T CY191100034T CY1121296T1 CY 1121296 T1 CY1121296 T1 CY 1121296T1 CY 20191100034 T CY20191100034 T CY 20191100034T CY 191100034 T CY191100034 T CY 191100034T CY 1121296 T1 CY1121296 T1 CY 1121296T1
Authority
CY
Cyprus
Prior art keywords
ghrelin
greelin
acylinated
prader
fragments
Prior art date
Application number
CY20191100034T
Other languages
English (en)
Inventor
Aart Jan Van Der Lely
Thierry Abribat
Original Assignee
Millendo Therapeutics Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millendo Therapeutics Sas filed Critical Millendo Therapeutics Sas
Publication of CY1121296T1 publication Critical patent/CY1121296T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)

Abstract

Μέθοδος και σύνθεση για μείωση επιπέδων γκρελίνης ή/και μείωση αναλογίας γκρελίνης/μη ακυλιωμένης γκρελίνης σε ένα υποκείμενο, η δε μέθοδος περιλαμβάνει χορήγηση αποτελεσματικής ποσότητας μη ακυλιωμένης γκρελίνης, θραύσματος αυτής, αναλόγου αυτής ή/και φαρμακευτικώς αποδεκτών αλάτων αυτής στο υποκείμενο, όπου μείωση στα επίπεδα γκρελίνης ή/και μείωση στην αναλογία γκρελίνης / μη ακυλιωμένης γκρελίνης είναι ευεργετική για το υποκείμενο. Επίσης, χρήση επιπέδου γκρελίνης ή/και αναλογίας γκρελίνης / μη ακυλιωμένης γκρελίνης ως βιοδείκτες για προσδιορισμό πιθανότητας ενός υποκειμένου σε ανταπόκριση προς χορήγηση ή/και όφελος από χορήγηση μη ακυλιωμένης γκρελίνης.
CY20191100034T 2011-12-15 2019-01-14 Θραυσματα μη ακυλιωμενης γκρελινης για χρηση στη θεραπεια συνδρομου prader-willi CY1121296T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576217P 2011-12-15 2011-12-15
PCT/IB2012/002867 WO2013088241A1 (en) 2011-12-15 2012-12-14 Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin

Publications (1)

Publication Number Publication Date
CY1121296T1 true CY1121296T1 (el) 2020-05-29

Family

ID=47780096

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100034T CY1121296T1 (el) 2011-12-15 2019-01-14 Θραυσματα μη ακυλιωμενης γκρελινης για χρηση στη θεραπεια συνδρομου prader-willi

Country Status (16)

Country Link
US (2) US20140336109A1 (el)
EP (1) EP2790721B8 (el)
JP (1) JP6031121B2 (el)
CA (1) CA2857276A1 (el)
CY (1) CY1121296T1 (el)
DK (1) DK2790721T3 (el)
ES (1) ES2705499T3 (el)
HR (1) HRP20190062T1 (el)
HU (1) HUE042102T2 (el)
LT (1) LT2790721T (el)
PL (1) PL2790721T3 (el)
PT (1) PT2790721T (el)
RS (1) RS58237B1 (el)
SI (1) SI2790721T1 (el)
TR (1) TR201900438T4 (el)
WO (1) WO2013088241A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6031121B2 (ja) 2011-12-15 2016-11-24 アリゼ ファーマ エスアーエス 非アシル化グレリンを使用したグレリンレベル及びグレリン／非アシル化グレリン比の調節
US20140378380A1 (en) 2013-06-21 2014-12-25 Alizé Pharma SAS Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
EP3193939A4 (en) * 2014-09-17 2018-10-24 The Regents of The University of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
CN113599386A (zh) * 2014-11-14 2021-11-05 伊森舍丽斯有限公司 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法
US10053693B2 (en) 2016-01-19 2018-08-21 Mubin I. Syed Method for controlling obesity using minimally invasive means

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US6627729B1 (en) 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
WO2001087335A2 (en) 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
WO2002060477A1 (en) 2001-01-31 2002-08-08 Human Genome Sciences, Inc. Scaffolded fusion polypeptides, compositions for making the same and methods of using the same
JP4493913B2 (ja) 2001-01-31 2010-06-30 中外製薬株式会社 低栄養症状疾患治療剤
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
ATE552031T1 (de) 2001-12-18 2012-04-15 Alize Pharma Sas Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
IL162796A0 (en) 2002-05-21 2005-11-20 Kenji Kangawa Medicinal compositions containing ghrelin
EP1694355A4 (en) 2003-10-24 2009-07-29 Alize Pharma Sas USE OF GHRELINE AND NON-ACYLATED GHRELINE COMPOSITIONS IN INSULIN RELATED DISEASES
WO2006045319A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
EP2021365B1 (en) 2006-03-28 2012-05-30 Liat Mintz A ghrelin splice variant for use in the prevention or treatment of high cholesterol levels
US8318664B2 (en) * 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
CN101678084B (zh) * 2007-05-31 2015-01-21 阿利兹药物股份有限公司 未酰基化的生长素释放肽作为治疗代谢紊乱中的治疗剂
EP2067481A1 (en) * 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin
US8476408B2 (en) * 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
JP6031121B2 (ja) 2011-12-15 2016-11-24 アリゼ ファーマ エスアーエス 非アシル化グレリンを使用したグレリンレベル及びグレリン／非アシル化グレリン比の調節

Also Published As

Publication number Publication date
DK2790721T3 (en) 2019-02-04
US20130157936A1 (en) 2013-06-20
LT2790721T (lt) 2019-02-11
WO2013088241A1 (en) 2013-06-20
US20140336109A1 (en) 2014-11-13
JP2015501832A (ja) 2015-01-19
HUE042102T2 (hu) 2019-06-28
EP2790721A1 (en) 2014-10-22
PT2790721T (pt) 2019-01-24
RS58237B1 (sr) 2019-03-29
SI2790721T1 (sl) 2019-03-29
HRP20190062T1 (hr) 2019-03-08
PL2790721T3 (pl) 2019-05-31
JP6031121B2 (ja) 2016-11-24
EP2790721B8 (en) 2018-11-28
US9550821B2 (en) 2017-01-24
TR201900438T4 (tr) 2019-02-21
CA2857276A1 (en) 2013-06-20
EP2790721B1 (en) 2018-10-17
ES2705499T3 (es) 2019-03-25

Similar Documents

Publication Publication Date Title
CY1121296T1 (el) Θραυσματα μη ακυλιωμενης γκρελινης για χρηση στη θεραπεια συνδρομου prader-willi
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1120374T1 (el) Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια
EA201490559A1 (ru) Композиция для лечения свища
EA201101053A1 (ru) Ингибиторы фосфоиноз итид-3-киназ с цинксвязывающей группой
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
MX2016004678A (es) Composiciones para el tratamiento del cancer.
CL2012003385A1 (es) Tratamiento para la incontinencia.
BR112015014876A2 (pt) composições e métodos para aperfeiçoar a solubilidade de rebaudiosídeo x
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
BR112013033166A2 (pt) método microbiológico de produção de uma solução de dextrano, solução de dextrano nativo e seu uso
MX371095B (es) Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
PH12015502405A1 (en) Methods and compositions for wound healing
EA201490268A1 (ru) Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор
MX339793B (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
CY1119413T1 (el) Μεθοδος για την παραγωγη και τη χρηση ενος συμπολυμερους νατριουχου καρβοξυμεθυλοκυτταρινης και γκοσυπολης
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
BR112015002531A2 (pt) composição, método de tratamento de hipersensibilidade e uso de carbonato de cálcio.
UA117455C2 (uk) Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора
WO2013074816A3 (en) Novel inhibitors of nox1
EA201390757A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА
EA201301080A1 (ru) Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания
CY1117742T1 (el) Ταπενταδολη για χρησιμοποιηση στη θεραπεια συνδρομου ευερεθιστου εντερου